Literature DB >> 29115302

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

Min Yuen Teo, Matthew J O'Shaughnessy, Sean M McBride, Herbert A Vargas, Howard I Scher.   

Abstract

This corrects the article DOI: 10.1038/nrclinonc.2017.160.

Entities:  

Year:  2017        PMID： 29115302     DOI： 10.1038/nrclinonc.2017.177

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  1 in total

1.  Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer.

Authors:  Benjamin A Gartrell; Mack Roach; Avi Retter; Gerald H Sokol; Giuseppe Del Priore; Howard I Scher
Journal:  Invest New Drugs       Date:  2020-09-13       Impact factor: 3.651
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.